(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A Couple of Modest Guitars for 2024 - 219 Peculiar Films You Shouldn't Watch With Your Mum
- 3Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- 4The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- 5A definitive Manual for Well known Fragrances
- Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- A Past filled with Old Civilizations: The World's Most established Societies
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works.
- San Francisco sues 10 companies that make ultraprocessed food
- Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
- 4 Famous Attractions at Disneyland
- Man triggers smoke bomb during failed crypto robbery
